CCA Summit Live from ESMO 2022

Videos — October 4, 2022

Featuring:

Juan W. Valle, MB ChB, MSc, FRCP
Professor and Honorary Consultant
Medical Oncology
Manchester Academic Health Sciences
Centre Institute of Cancer Studies
University of Manchester
Lead, The Christie European
Neuroendocrine Tumour Society
Centre of Excellence
Manchester, UK
On September 21, 2022, I presented an overview of key abstracts on biliary tract cancer (BTC) presented at the 2022 annual meeting of the European Society for Medical Oncology. In addition, I provided my perspective on the impact of the data on the management of patients with BTC.

Related Items

Hot Topics on Cholangiocarcinoma at the 2023 Cholangiocarcinoma Foundation Annual Conference
By Melinda Bachini; Juan W. Valle, MB ChB, MSc, FRCP
Videos
On April 14, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 Cholangiocarcinoma Foundation Annual Conference.
The Impact of mFOLFOX Chemotherapy in Conjunction with Active Symptom Control on Patient QOL: The ABC-06 Trial
Web Exclusives
Preliminary analyses of patient quality-of-life data from the ABC-06 clinical trial suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
Derazantinib Shows Clinical Efficacy in the Treatment of iCCA in Patients with Genetically Aberrant FGFR2
Web Exclusives
Data from the FIDES-01 clinical trial showed encouraging results for derazantinib as a second-line treatment for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions, mutations, or amplification.
Real-World Evidence for Liquid Biopsy to Identify Molecular Alterations
Web Exclusives
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations, offering personalized treatment options.
FGFR Inhibitor RLY-4008 Shows Promise in Treating Metastatic CCA
Web Exclusives
Early data from the ReFocus trial indicated that the highly selective FGFR2 inhibitor RLY-4008 may be an effective new treatment for cholangiocarcinoma in patients with FGFR2 fusions or rearrangements.
Nanoliposomal Irinotecan Combination Therapy Falls Short in Metastatic BTC
Web Exclusives
The NALIRICC study compared the efficacy of nanoliposomal irinotecan plus 5-fluorouracil (5-FU) plus leucovorin (LV) with 5-FU plus LV on progression-free and overall survival in patients with biliary tract cancer.
Tislelizumab as Part of a Conversion Therapy Regimen for Potentially Resectable Biliary Tract Cancers
Web Exclusives
A phase 2 study found that the combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin showed promise as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer, making curative surgery a possibility for some patients.
Additional 6-Month Follow-up from the TOPAZ-1 Study Comparing Durvalumab with Placebo plus Gem/Cis in Patients with Advanced BTC
Web Exclusives
Updated overall survival (OS) and safety data from the TOPAZ-1 study revealed improved median OS for the full patient population as well as subgroup analyses and an adverse event profile consistent with previously reported data.
Immune-Related Adverse Events in the TOPAZ-1 Study of Durvalumab or Placebo plus GemCis in Advanced BTC
Web Exclusives
Analysis of the safety population in the TOPAZ-1 trial in patients with biliary tract cancer revealed that immune-related adverse events were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.
Molecular Epidemiology in CCA
By Juan W. Valle, MB ChB, MSc, FRCP; Lewis R. Roberts, MB, ChB, PhD
Videos
Dr Lewis Roberts discusses molecular biomarkers that may correlate with known epidemiological risk factors associated with the incidence of cholangiocarcinoma, and the types of preclinical and clinical studies that are needed to explore these correlations.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: